19736 S0491 M1 1571
Document text
BioNTech SE 09/15/2021 An der Goldgrube 12 Mainz Rhineland-Palatinate Germany 55131(214) 918-5262 COVID-19 Vaccine (BNT162, PF-07302048) 019736 Active immunization to prevent COVID-19 caused by SARS-CoV-2 BB-IND 013812, BB-IND 013278, BLA 125549 0 4 9 1 3 FDA-CBER-2021 5683-1122587 Özlem Türeci, MD, Chief Medical Officer, BioNTech SE Özlem Türeci, MD, Chief Medical Officer, BioNTech SE Amit Patel, Director, Global Regulatory Affairs - Vaccines 214-918-5262 (845) 474-3500 235 East 42nd Street New York NY United States of America [email protected] 09/15/2021 United States of America 3 (b) (6) FDA-CBER-2021-5683-1122588 3 FDA-CBER-2021-5683-1122589